Rosuvastatin at doses of 5 to 80 mg significantly reduced mean triglyceride levels by 18% to 40% compared with a 2.9% increase with placebo (P≤0.001).
RCT (n=156)
Double-blind
parallel-group
Sí
Does rosuvastatin improve triglyceride levels and lipid profiles in patients with hypertriglyceridemia?
Rosuvastatin significantly reduces triglyceride levels and improves atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.
valor p: p=≤ 0.001
BACKGROUND: We examined the effects of rosuvastatin treatment on triglyceride levels and lipid measures in a parallel-group multicenter trial (4522IL/0035) in patients with hypertriglyceridemia (Fredrickson Type IIb or IV). METHODS: After a 6-week dietary lead-in period while on a National Cholesterol Education Program step I diet, 156 patients with fasting triglyceride levels >/= 300 and 5 mg. The occurrence of adverse events was generally low and not dose related, although some adverse events occurred more frequently in the rosuvastatin 80 mg group. CONCLUSIONS: Rosuvastatin reduced triglyceride levels and improved the overall atherogenic and atheroprotective lipid profiles in hypertriglyceridemic patients.
Hunninghake et al. (Thu,) conducted a rct in hypertriglyceridemia (n=156). rosuvastatin vs. placebo was evaluated on mean percentage change from baseline in total serum triglyceride levels at week 6 (p=≤ 0.001). Rosuvastatin at doses of 5 to 80 mg significantly reduced mean triglyceride levels by 18% to 40% compared with a 2.9% increase with placebo (P≤0.001).